cd19 depletion Search Results


90
Johns Hopkins HealthCare haploidentical hct with tcr+ t cell/cd19+ depletion
Haploidentical Hct With Tcr+ T Cell/Cd19+ Depletion, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd19+depletion/haploidentical+hct+with+tcr++t+cell+cd19++depletion/10__1016_slash_s2666___6367_ascii40_23_ascii41_00464___5-61-28-36
Average 90 stars, based on 1 article reviews
haploidentical hct with tcr+ t cell/cd19+ depletion - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
ExVivo Labs tcrαβ/cd19 depleted graft
Clinical trials and case reports of VEXAS patients who have undergone allo-HCT
Tcrαβ/Cd19 Depleted Graft, supplied by ExVivo Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd19+depletion/cd3+++cd19++depleted+stem+cell+grafts/pmc11535077-5-97-97
Average 90 stars, based on 1 article reviews
tcrαβ/cd19 depleted graft - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Clinical trials and case reports of VEXAS patients who have undergone allo-HCT

Journal: Annals of Hematology

Article Title: Role of allogeneic hematopoietic cell transplantation in VEXAS syndrome

doi: 10.1007/s00277-024-05942-2

Figure Lengend Snippet: Clinical trials and case reports of VEXAS patients who have undergone allo-HCT

Article Snippet: EBMT multicenter study [ ] , 19 , RIC-74%, MAC − 26% Fludarabine based; Flu/Bu ( n = 7), treosulfan ( n = 4), Bu/Thiotepa ( n = 3), melphalan ( n = 2), 1 received TBI), melphalan and thiotepa ( n = 1), FLAMSA/Bu- Cy sequential combination ( n = 2). , MSD: 16%, MUD: 63% MMRD: 16% MMUD: 5% , PBSC:18 BM:1 , PT Cy [day + 3/+4] n = 6, ATG [ n = 11] or alemtuzumab [ n = 2 ] + Cyclo/methotrexate [ n = 7] or MMF [ n = 5]. Exvivo TCRαβ/CD19 depleted graft ( n = 1). , Grade II-IV acute GVHD: 26% Chronic extensive GVHD: 4 , 2 -year OS: 74.2% at 14 months from allo-HCT, TRM: 25.8% 94% full donor chimerism. UBA1 disappearance in 6 patients. , 4 deaths, 3 died due to infection and 1 from CNS toxicity..

Techniques: Clinical Proteomics, Virus, Infection, Mutagenesis